TABLE 3.

Novel drug regimen clinical outcomes sorted by initial treatment goal

N = 124	Curative	Palliative	Temporizing	Bridging to BMT	Other	Overall
Responders (N = 91) (%)
Complete remission	9 (13.2)	1 (3.3)	0 (0.0)	7 (70.0)	0 (0.0)	17 (13.7)
Partial remission	22 (32.4)	4 (13.3)	2 (14.3)	1 (10.0)	0 (0.0)	29 (23.4)
Stable disease	19 (27.9)	13 (43.3)	9 (64.3)	0 (0.0)	1 (50.0)	42 (33.9)
Mixed response	2 (2.9)	1 (3.3)	0 (0.0)	0 (0.0)	0 (0.0)	3 (2.4)
Ongoing responses (%)	22 (32.4)	4 (13.3)	7 (50.0)	2 (20.0)	0 (0.0)	35 (28.2)
Median duration (months)	40.3	7.9	19.7	25.13	0	24.0
Range of duration (months)	3.68‐93.2	0‐23.72	14.39‐37.06	24.8‐25.46	0	0‐93.2
Ceased responses (%)	29 (42.6)	15 (50.0)	4 (28.6)	6 (60.0)	1 (50.0)	55 (44.4)
Median duration (months)	9.6	5.03	9.4	3.0	21.9	6.7
Range of duration (months)	0.76‐27.53	0.2‐33.97	1.74‐18.17	1.25‐25.56	21.9	0.2‐33.97
Lost to follow‐up (%)	1 (1.5)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.8)
Non‐responders (N = 33) (%)
Disease progression	9 (13.2)	7 (23.3)	0 (0.0)	0 (0.0)	0 (0.0)	16 (12.9)
No response recorded	7 (10.3)	4 (13.3)	3 (21.4)	2 (20.0)	1 (50.0)	17 (13.7)
Total regimens reported	68	30	14	10	2	124

Abbreviation: BMT, bone marrow transplant.